Ambrisentan Patent Expiration
Ambrisentan is used for treating pulmonary arterial hypertension (PAH) in combination with tadalafil by inhibiting endothelin receptors. It was first introduced by Gilead Sciences Inc
Ambrisentan Patents
Given below is the list of patents protecting Ambrisentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Letairis | US5703017 | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec 30, 2014
(Expired) | Gilead |
| Letairis | US5840722 | Use of carboxylic acid derivatives as drugs |
Nov 24, 2015
(Expired) | Gilead |
| Letairis | US7109205 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US7601730 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US8349843 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US8377933 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | US9474752 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | US9549926 | Compositions and methods of treating pulmonary hypertension | Oct 14, 2031 | Gilead |
| Letairis | USRE42462 | Carboxylic acid derivatives, their preparation and use |
Jul 29, 2018
(Expired) | Gilead |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Ambrisentan Generics
Several generic applications have been filed for Ambrisentan. The first generic version for Ambrisentan was by Watson Laboratories Inc and was approved on Mar 28, 2019. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Jul 21, 2022.
Given below is the list of companies who have filed for Ambrisentan generic.
1. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
2. SIGMAPHARM LABS LLC
Sigmapharm Laboratories Llc has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Sigmapharm Labs Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Apr 10, 2019 |
| 5MG | tablet | Prescription | ORAL | AB | Apr 10, 2019 |
3. CIPLA
Cipla Ltd has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Apr 26, 2019 |
| 10MG | tablet | Prescription | ORAL | AB | Apr 26, 2019 |
4. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
5. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Jul 21, 2022 |
| 10MG | tablet | Prescription | ORAL | AB | Jul 21, 2022 |
6. ENDO OPERATIONS
Endo Operations Ltd has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Discontinued | ORAL | N/A | Apr 10, 2019 |
| 5MG | tablet | Discontinued | ORAL | N/A | Apr 10, 2019 |
7. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
| 10MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
8. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Prescription | ORAL | AB | May 19, 2022 |
| 10MG | tablet | Prescription | ORAL | AB | May 19, 2022 |
9. WATSON LABS INC
Watson Laboratories Inc has filed for 2 different strengths of generic version for Ambrisentan. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |
| 5MG | tablet | Prescription | ORAL | AB | Mar 28, 2019 |